Evidence map›Paper›PMID 40266434›Full record

ArticleCurrent medical science2025

Targeting Calprotectin S100A8/A9 to Overcome AML Progression in DNMT3A-Mutant Cells.

Xiao-Ya Cai, Gui-Qin Huang, Ye-Ming Zhou, Deng-Ju Li

Abstract read
PubMed Publisher
In one paragraph

Article in Current medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiao-Ya CaiDepartment of Hematology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430030, China.
Gui-Qin HuangDepartment of Hematology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430030, China.
Ye-Ming ZhouDepartment of Hematology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430030, China.
Deng-Ju LiDepartment of Hematology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430030, China. lidengju@tjh.tjmu.edu.cn.ORCID https://orcid.org/0000-0001-7629-2642

Funding

Ministry of Education 82270177the China Medicine Education Association 2024 Medical Science and Technology Research Project 2024KTZ035
6 · The paper itself

Abstract

objectiveTo investigate the effects of calprotectin (S100A8/A9) on the biological activity of acute myeloid leukemia (AML) cells harboring a DNA methyltransferase 3A (DNMT3A) mutation and to explore the underlying molecular mechanisms involved.

methodsAML monoclonal cell lines harboring the DNMT3A

resultsDifferential gene expression analysis revealed 442 upregulated and 535 downregulated genes in DNMT3A-mutated (DNMT3A

conclusionElevated S100A8/A9 expression contributes to the abnormal proliferation, migration, adhesion, and chemoresistance of DNMT3A

Indexed as

Calgranulin ACalgranulin BDNA (Cytosine-5-)-MethyltransferasesLeukemia, Myeloid, AcuteLeukocyte L1 Antigen ComplexApoptosisCell AdhesionCell Line, TumorCell MovementCell ProliferationDisease ProgressionDNA Methyltransferase 3AFemaleGene Expression Regulation, LeukemicHumansMaleCalgranulin ACalgranulin BDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanLeukocyte L1 Antigen ComplexQuinolonesS100A8 protein, humanS100A9 protein, humanAcute myeloid leukemiaDNA methyltransferase 3AS100A8S100A9

Identifiers

PMID40266434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.